Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
about
Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*The renaissance of fixed dose combinations: CombivirEvolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatmentMinority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacyOptimal Treatment Strategies in the Context of 'Treatment for Prevention' against HIV-1 in Resource-Poor SettingsMethodological standards in non-inferiority AIDS trials: moving from adherence to compliance.Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapyAbacavir/lamivudine combination in the treatment of HIV: a review.Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysisPharmacogenetics of drug hypersensitivity.48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.Zidovudine and Lamivudine for HIV Infection.Immune restoration disease and changes in CD4+ T-cell count in HIV- infected patients during highly active antiretroviral therapy at Zewditu memorial hospital, Addis Ababa, Ethiopia.Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in JapanDeficient reporting and interpretation of non-inferiority randomized clinical trials in HIV patients: a systematic review.Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT)Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011-2012.Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trialsFixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection.Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan.Individualization of antiretroviral therapy.British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).Abacavir/lamividune combination in the treatment of HIV-1 infection: a review.Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients.Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.Antiretroviral treatment of HIV infection: Swedish recommendations 2007.Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview.Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.Pharmacogenetic information derived from analysis of HLA alleles.Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials.Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study.A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma.Efavirenz: a decade of clinical experience in the treatment of HIV.Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.Successful translation of pharmacogenetics into the clinic: the abacavir example.HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects.Causes and consequences of incomplete HIV RNA suppression in clinical trials.
P2860
Q27015850-A16C0E79-7312-4838-A7E0-A3FF555EEC1FQ28279752-88B49712-7DCD-43B1-B8E5-242753658D28Q28471623-0C65E056-D467-4721-8F0B-6297E6595A6EQ28473296-329FD6BD-CFC5-4285-A466-9D2B4E797381Q28547109-7401A40F-0E77-45AF-8596-8A8B27873F7FQ33258171-5854E7BE-6EFB-472F-85CC-35ADE03CFAA3Q33565604-3B040E8E-C254-47F5-9DB1-D9D2D1E9CE9CQ33715435-66E43ABA-F9F0-4812-B2FD-0ADB535111FBQ33988153-7EE590D5-4BC6-4571-9939-7420F47DB4B3Q34118186-6828CD11-A6E3-431E-B05F-DD90A3D2D3E3Q34134900-910927CD-5085-434C-8835-D6A46D9E09E8Q34194561-3E17E305-1392-4BA6-9246-B79F47F4870CQ34499007-F3EE5FFF-5725-44CD-A70B-705B59980168Q34503452-52B34F39-1DA0-464F-905D-3B26EA0584FAQ34713094-6BFA5BFE-F37E-41B2-97BE-E3DE84C82853Q35214141-F6A74F71-C2C7-45FA-B195-C2ECC2772B9BQ35233168-747624B6-0F99-4A39-898D-77C8920098FBQ35959086-D6E6545B-C9F7-49D3-A75C-BF192678CE5EQ36156655-05C7D43E-B964-4D7C-BDD3-271B29A1D0A0Q36198650-38F63C21-1A95-4995-A503-55639DA46806Q36276597-9E97A60D-78DF-4DD6-9A85-AB10F0505899Q36322100-51F16656-E12C-426A-9469-A8C428F6EA99Q36343668-B33AC237-6A9E-4D59-B488-897333D510E2Q36441423-F0B26340-4E9A-4B41-A3A4-AE901A7EE38BQ36653838-94676917-D988-42F4-86E3-81FAA7315570Q36675417-F19E7FF9-31FE-492B-BA8B-256E733CD8D3Q36688943-2662EEBD-0685-4114-82F7-159AB75F4496Q36718901-17AEB858-0A1D-4354-B976-DCEFBC5A35D6Q36852859-627C2A09-3646-4E8E-A045-C4CCE1996510Q36919659-37082F0E-8376-4BA1-BEAD-879E17261109Q37107177-4A0B27C1-361F-4043-A436-D88342CB84FCQ37120841-B25D3D4F-8EB9-4000-BAE1-B3E38D74C4D9Q37228748-13F8820F-C68C-4066-A86D-39C2FDE74EE6Q37328870-7CAAC702-B3CE-4D65-B488-392F719DBA09Q37365825-1F06182C-8025-4523-9D35-B720983AA421Q37383949-FFF5498C-C27C-477C-9853-BD1C00C97065Q37389496-8B0EA31B-D5CA-4114-9A86-FFCB855939A8Q37436365-963435C8-0767-44F4-A29D-7C0EE6379B57Q37514235-60243191-38C8-4836-8F70-1B356C5BF0EEQ37631282-E97601D6-F197-4E5E-8E01-04B7505D1279
P2860
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Abacavir versus zidovudine com ...... ral-naive HIV-infected adults.
@en
Abacavir versus zidovudine com ...... ral-naive HIV-infected adults.
@nl
type
label
Abacavir versus zidovudine com ...... ral-naive HIV-infected adults.
@en
Abacavir versus zidovudine com ...... ral-naive HIV-infected adults.
@nl
prefLabel
Abacavir versus zidovudine com ...... ral-naive HIV-infected adults.
@en
Abacavir versus zidovudine com ...... ral-naive HIV-infected adults.
@nl
P2093
P356
P1476
Abacavir versus zidovudine com ...... ral-naive HIV-infected adults.
@en
P2093
CNA30024 Study Team
Carlos Beltran Buendia
Cynthia H Brothers
E Randall Lanier
Edwin DeJesus
Eugenio Teofilo
Gisela Herrera
J David Brand
Jaime Hernandez
Jan Gerstoft
P304
P356
10.1086/424009
P407
P577
2004-09-10T00:00:00Z